Literature DB >> 11699663

High-resolution CT of diffuse lung disease: value and limitations.

D M Hansell1.   

Abstract

The relative speed with which HRCT has become the imaging technique of choice for evaluating patients with suspected lung disease can be regarded as a testament to its effectiveness. It is as well, however, to remember some of the caveats that apply to the interpretation of the numerous studies that have championed the clinical application of HRCT. It seems unlikely that CT will be supplanted in the near future by other cross-sectional or volumetric imaging techniques for the evaluation of diffuse lung disease. The scope for further technical refinement of the hardware aspects of HRCT is probably limited but improvements in postprocessing of image data, with the potential to advance understanding of the pathophysiology of diffuse lung disease, can be anticipated.

Entities:  

Mesh:

Year:  2001        PMID: 11699663     DOI: 10.1016/s0033-8389(05)70333-x

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  3 in total

1.  The clinical impact of high resolution computed tomography in patients with respiratory disease.

Authors:  Nicholas J Screaton; Fiona N A C Miller; Bipen D Patel; Ashley Groves; Angela D Tasker; David A Lomas; Christopher D R Flower
Journal:  Eur Radiol       Date:  2010-08-24       Impact factor: 5.315

2.  High-resolution computed tomography and magnetic resonance imaging protocols in the diagnosis of fibrotic interstitial lung disease: overview for "non-radiologists".

Authors:  Gianluigi Sergiacomi; Luca Pugliese; Francesca Ricci; Roberto Floris; Armando Fusco
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 3.  The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases.

Authors:  Andor W J M Glaudemans; Erik F J de Vries; Filippo Galli; Rudi A J O Dierckx; Riemer H J A Slart; Alberto Signore
Journal:  Clin Dev Immunol       Date:  2013-08-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.